Rapamycin nanoparticles improves drug bioavailability in PLAM treatment by interstitial injection
- PMID: 36085075
- PMCID: PMC9463820
- DOI: 10.1186/s13023-022-02511-6
Rapamycin nanoparticles improves drug bioavailability in PLAM treatment by interstitial injection
Abstract
Background: Pulmonary lymphangiomyomatosis (PLAM) is a rare interstitial lung disease characterized by diffuse cystic changes caused by the destructive proliferation of smooth muscle-like cells or LAM cells. PLAM is more common in young women than other people, and a consensus is lacking regarding PLAM treatment. The clinical treatment of PLAM is currently dominated by rapamycin. By inhibiting the mTOR signaling pathway, rapamycin can inhibit and delay PLAM's occurrence and development. However, the application of rapamycin also has shortcomings, including the drug's low oral bioavailability and a high binding rate to hemoglobin, thus significantly decreasing the amount of drug distributed to the lungs.
Methods and results: Here, we developed a new mode of rapamycin administration in which the drug was injected into the intrathecal space after being nanosized; the directional flow characteristics of the liquid in the intrathecal space were exploited to increase the drug content in the interstitial fluid to the greatest extent possible. We studied the rapamycin content in the interstitial fluid and blood after intervaginal space injection (ISI). Compared with oral administration, ISI significantly increased the drug concentration in the lung interstitial fluid.
Conclusions: These results provided new ideas for treating PLAM and optimizing the dosing regimens of drugs with similar characteristics to rapamycin.
Keywords: Intervaginal space injection (ISI); LC–MS; Pulmonary lymphangiomyomatosis (PLAM); Rapamycin.
© 2022. The Author(s).
Conflict of interest statement
The authors declare that they have no competing interests.
Figures



Similar articles
-
Regression of pulmonary lymphangioleiomyomatosis (PLAM)-associated retroperitoneal angiomyolipoma post-lung transplantation with rapamycin treatment.J Heart Lung Transplant. 2008 Apr;27(4):462-5. doi: 10.1016/j.healun.2008.01.005. J Heart Lung Transplant. 2008. PMID: 18374885
-
Inhaled rapamycin solid lipid nano particles for the treatment of Lymphangioleiomyomatosis.Eur J Pharm Sci. 2020 Jan 15;142:105098. doi: 10.1016/j.ejps.2019.105098. Epub 2019 Nov 5. Eur J Pharm Sci. 2020. PMID: 31698038
-
Pulmonary lymphangioleiomyomatosis in a 46-year-old female: A case report and review of the literature.Biomed Rep. 2016 Jun;4(6):719-722. doi: 10.3892/br.2016.652. Epub 2016 Apr 13. Biomed Rep. 2016. PMID: 27284412 Free PMC article.
-
Prospective nanoparticle treatments for lymphangioleiomyomatosis.Expert Opin Drug Deliv. 2022 Jan;19(1):75-86. doi: 10.1080/17425247.2022.2029401. Epub 2022 Jan 21. Expert Opin Drug Deliv. 2022. PMID: 35043744 Review.
-
[Clinicopathologic analysis of pulmonary lymphangioleiomyomatosis].Zhonghua Bing Li Xue Za Zhi. 2005 Feb;34(2):84-7. Zhonghua Bing Li Xue Za Zhi. 2005. PMID: 15842802 Review. Chinese.
Cited by
-
Combined rapamycin and mesenchymal stem/stromal cells derived from induced pluripotent stem cells-mediated delivery of ACVR2B-Fc fusion protein reduces heterotopic ossification in a mouse model of fibrodysplasia ossificans progressiva.JBMR Plus. 2025 Apr 21;9(6):ziaf068. doi: 10.1093/jbmrpl/ziaf068. eCollection 2025 Jun. JBMR Plus. 2025. PMID: 40416557 Free PMC article.
-
The bioavailability and blood levels of low-dose rapamycin for longevity in real-world cohorts of normative aging individuals.Geroscience. 2025 Jan 28. doi: 10.1007/s11357-025-01532-w. Online ahead of print. Geroscience. 2025. PMID: 39873920
-
Self-assembled vectors derived from Aster tataricus L.f. mitigate bleomycin-induced pulmonary fibrosis in mice.Mater Today Bio. 2025 May 29;32:101901. doi: 10.1016/j.mtbio.2025.101901. eCollection 2025 Jun. Mater Today Bio. 2025. PMID: 40520551 Free PMC article.
References
-
- Feng J, et al. A “green pathway” different from simple diffusion in soft matter: fast molecular transport within micro/nanoscale multiphase porous systems. Nano Res. 2014;7(3):434–442. doi: 10.1007/s12274-014-0409-z. - DOI
-
- Li H, et al. Longitudinal non-vascular transport pathways originating from acupuncture points in extremities visualised in human body. Chin Sci Bull. 2014;59(35):5090–5095. doi: 10.1007/s11434-014-0633-7. - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous